Skip to content
Bomb Report – Lifestyle
Author:
Global Down Syndrome Foundation
Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
May 21, 2026
Lilly’s Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
May 13, 2026
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility
May 7, 2026
Lilly’s Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years
May 5, 2026
New Research Published in Hotel Business: Inclusive Hiring May be Hospitality’s Retention Cure
April 30, 2026
ACHIEVE-4, the longest Phase 3 study of Lilly’s Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
April 16, 2026
Foundayo™ (orforglipron), Lilly’s new oral GLP-1 pill for weight loss, now available in the U.S.
April 9, 2026
FDA approves Lilly’s Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions
April 1, 2026
Phase 3b data presented at AAD Annual Meeting show Lilly’s Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity
March 30, 2026
GLOBAL Marks World Down Syndrome Day with Publication of Milestone Review of New Medical Guideline
March 20, 2026
←
Previous Page
1
2
3
Next Page
→